On 21 November, Neurofix Pharma presented the successful results of phase IIA of the clinical trial of the pioneering drug it is developing against neuropathic pain caused by spinal cord injury to the Salamanca society. The event took place at the Arzobispo Fonseca school, also with the aim of highlighting Salamanca’s potential as a biotechnology […]
“Your success generates opportunities, employment, wealth and improves people’s quality of life”. The president of the Regional Government of Castilla y León, Alfonso Fernández Mañueco, visited the offices of Neurofix Pharma in the Science Park of the University of Salamanca this Friday to support the first biotech company in Castilla y León to successfully complete […]
The Spanish biotech Neurofix Pharma has taken another step in its goal of improving the quality of life of patients with spinal cord injury. The European Innovation Council has confirmed to the company its passage to the last phase of the EIC Accelerator initiative, the most popular European financing line for companies that want to […]
Neurofix Pharma will participate in the major biotechnology events.24 de August de 2023 - 13:33
Neurofix Pharma presents the successful results of its phase IIA clinical trial to institutions and businessmen in Salamanca28 de November de 2022 - 08:46
Mañueco visits the offices of Neurofix Pharma, the first biotech company in Castilla y León to successfully complete phase IIA of a clinical trial11 de November de 2022 - 15:42